Chemotherapy Market 2017 to 2025 – Global Industry Size, Share, Analysis, Trend & Future Strategic Planning

Market Synopsis
Chemotherapy is drug therapy used in the treatment of cancer. Chemotherapy prevents cancer cells from growing and it does this by killing the dividing cells. When chemotherapy drugs travel through the bloodstream to reach cells throughout the body, it is called as systemic and when drugs are directed towards a particular area of the body it is named as regional chemotherapy. It can treat various types of cancer including leukemia, breast cancer, sarcoma, lung cancer, ovarian cancer, lymphoma and many others. Despite chemotherapy is widely used treatment it has number of side effects as therapy also damages healthy cells. It shows side effects such as hair loss, nausea, vomiting, hearing impairment, fatigue, loss of appetite, mucositis and other. According to the American Cancer Society in 2017, there will be an estimated 1.6 million new cancer cases diagnosed and 0.6 million cancer deaths in the US.

Rising number of cancer cases globally, rising exposure of people to radiation &carcinogenic agents, are the major factors driving the growth of chemotherapy market. According to the Cancer Research U.K 14.1 million new cancer cases were reported globally in 2012 boosting the growth of the market. Additionally factors such as alcohol consumption, smoking & bad food habits, and obesity can cause cancer flourishes market growth. Furthermore, the advancement in technology, surging attention to research and development in the field of oncology and government supportive programs will boost the growth of the market. Moreover, increasing awareness among population and developing healthcare infrastructure is anticipated support the growth of chemotherapy market. However, severe side effects of the therapy and presence of alternative treatment options such as biological & targeted drug therapy and risk associated with the treatment may act as deterrent causing sluggish growth of the market.

Request for a sample copy of this report @ http://bit.ly/2OBDoDJ

Segmentation
The global chemotherapy market is segmented on the basis of drugs, types, route of drug administration, and end-user.
On the basis of drugs, it is segmented into alkylating agents, anti-tumor antibiotics, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and others. Alkylating agents are further segmented into alkyl sulfonates, mustard gas derivatives, ethylenimines, hydrazines and triazines, and others. Anti-tumor antibiotics are further segmented into chromomycin and anthracyclines.
Topoisomerase inhibitors are further segmented into Topoisomerase I inhibitors and Topoisomerase II inhibitors.
On the basis of types, the market is segmented into blood cancer, lung cancer, lymphatic cancer, breast cancer, ovarian cancer, myeloma, and others.
On the basis of route of drug administration, the market is segmented into oral and parenteral.
On the basis of end-user, it is segmented into hospitals & clinics, research institutes, and others.

Regional Analysis
Geographically, the global chemotherapy market is segmented into four major regions: North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa. The chemotherapy market growth in America is driven by upsurge in affected population, existence of key market players producing chemotherapy drugs and growing expenses on healthcare facilities. According to American Cancer Society more than 15.5 million teenagers and adults with a history of cancer were alive on January 1, 2016 in the US. Besides, drastically changing lifestyle, high consumption of alcohol and smoking habits propels the market growth. National expenditure for cancer care in the US came up near about $ 125 billion in 2010 and could reach $ 156 billion by 2020. Europe chemotherapy market is propelled by increasing number of patients diagnosed with cancer.

View Full Report @ http://bit.ly/2nGCeeB

According to WHO Europe comprises only one eighth population of the total world population but has around one quarter of the global total cancer cases with some 3.7 million new patients per year. Asia-Pacific market is anticipated to be the fastest growing region attributed to high prevalence of various types of cancer in developing country, comparatively low cost of clinical research in this region due to large population base and favourable government policies. LAMEA is expected to witness steady growth in this market. Being mature market for chemotherapy Middle East will develop slowly whereas chemotherapy market in Africa has more substantial potential. Highest rate of population growth and less develop healthcare sector provides high opportunities for chemotherapy market in Africa.

Key Players
Sanofi, Novartis, Eli Lilly & Company, Pfizer Inc., AstraZeneca, GlaxoSmithKline, Teva Pharmaceuticals Industries, Bristol-Myers Squibb, Bayer AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Boehringer Ingelheim, and others.

About Us:
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.

Contact Us:
Kevin Thomas
Contact No: +1 513 549 5911 (US)
+44 203 318 2846 (UK)
Email: sales@garnerinsights.com

This release was published on openPR.